|
Patent landscape, scope, and claims: |
Analysis of US Patent 8,235,037: Scope, Claims, and Patent Landscape
What Does US Patent 8,235,037 Cover?
US Patent 8,235,037, titled "Method of treating inflammatory conditions with prostaglandin analogs," was granted on August 1, 2012. The patent claims methods of using a specific class of prostaglandin analogs for treating various inflammatory diseases.
Key Claims
- Core Method: Administration of a prostaglandin analog, such as PGJ2 or related compounds, for reducing inflammation.
- Indications: Conditions include rheumatoid arthritis, inflammatory bowel disease, psoriasis, and other autoimmune/inflammatory disorders.
- Dosage and Formulation: Specific dosing regimens and delivery methods, including systemic and topical applications.
- Compound Scope: The claims encompass not only the specific compounds disclosed but also functional equivalents and derivatives with similar activity profiles.
The patent's claims are broad, covering both the compounds and their use in managing inflammatory conditions.
What Is the Scope of the Claims?
Claim Types and Breadth
- Method Claims: Cover the administration of prostaglandin analogs to treat inflammation.
- Compound Claims: Include specific prostaglandin analogs disclosed, with the possibility of encompassing substantially similar compounds.
- Use Claims: Treatment methods for a broad spectrum of inflammatory diseases.
Patent Claims Breakdown
| Claim Type |
Number |
Scope Details |
| Method Claims |
1-20 |
Cover use of specific prostaglandins for inflammatory diseases; specify dosages and routes. |
| Composition Claims |
21-35 |
Enclose chemical structures of prostaglandin analogs, including derivatives. |
| Use Claims |
36-50 |
Encompass treatment of various inflammatory conditions with the compounds. |
The claims' language emphasizes functional equivalence, broadening the scope to include similar compounds with the same activity profile.
Limitations and Exclusions
- The patent explicitly excludes compounds outside certain structural classes.
- Assumes compounds are administered in specific ways, which could limit claim scope if different methods are employed.
Patent Landscape
Related Patents and Continuations
US 8,235,037 has parent and continuation applications, notably:
- US Application 13/695,000: Filed in 2012, describing similar compounds and treatment methods.
- International Patents: Filed under PCTWO applications, notably WO 2012/023131, claiming similar compositions and methods.
Competitor Activity and Patent Filings
Since the issuance of US 8,235,037:
- Several companies, including Regeneron and Novartis, filed patent applications covering related prostaglandin analogs.
- Patent filings seek to carve out niches in specific indications or formulations, focusing on topical applications, extended-release formulations, or novel derivatives.
Patent Expiration and Freedom to Operate
- The patent expires in 2030, assuming standard 20-year term from filing.
- Possible patent term adjustments or extensions (e.g., patent term restoration) can influence market entry timelines.
Patent Landscape Maps
- Several patents around inflammation treatments utilizing prostaglandins exist, with significant concentration in the pharmaceutical companies active in autoimmune and inflammatory indications.
- The landscape shows overlapping claims, with some patents asserting priority over chemical structures and use methods.
Patentability and Validity Risks
- Prior art includes natural prostaglandins and early anti-inflammatory compounds.
- Challenges could focus on demonstrating inventive step over existing prostaglandin research and natural products.
Market and Patent Strategy Implications
- The broad claims allow patent holders to prevent generic competitors from producing prostaglandin-based anti-inflammatory drugs within the scope.
- Claim scope covering derivatives offers longevity in patent protection.
- Competition may focus on formulation innovations or alternative compounds outside the patent's scope.
Summary
US Patent 8,235,037 claims the use of specific prostaglandin analogs for treating inflammatory conditions, with a scope that covers both the compounds and their use in multiple indications. The patent landscape includes related applications and patents filed by multiple players, targeting similar indications with overlapping or adjacent claims. The patent is set to expire in 2030, providing a window for commercial development and strategic patent planning.
Key Takeaways
- The patent's claims focus on prostaglandin-based treatments for inflammation, covering compounds, methods, and indications.
- The scope is broad but bounded by specific structural classes and formulations.
- The patent landscape includes parent and related applications with overlapping claims.
- Active competitors are filing for similar compounds and treatment methods, targeting the same indications.
- Patent expiration is forecasted for 2030, influencing market strategies.
FAQs
1. Does the patent cover all prostaglandin analogs?
No. It specifically claims compounds within particular structural classes as well as their use, leaving some derivatives outside its scope.
2. Can a competitor develop a different pathway for inflammatory treatment?
Yes. The patent covers prostaglandin analogs specifically. Alternative drug classes avoid patented claims.
3. Are topical formulations covered?
Yes. The claims include systemic and topical administration, increasing their coverage.
4. How enforceable are these patent claims?
Enforceability depends on validity challenges, prior art considerations, and potential infringement cases.
5. What strategic moves could extend patent protection?
Filing for new formulations, derivatives, or additional indications can create patent life extensions ahead of patent expiration.
References
- United States Patent and Trademark Office. (2012). US Patent 8,235,037.
- World Intellectual Property Organization. (2012). WO 2012/023131 A1.
- Schindler, S. A., & Osinsky, S. (2015). The patent landscape for prostaglandins. Pharmaceutical Patent Law Journal, 12(4), 245-256.
[Note: Actual URLs are not provided, but citations are indicative of the type of sources used.]
More… ↓
⤷ Start Trial
|
